Developments include $7.8 million cash position, go public transaction and financing, FDA clinical trial progress, licensing expansion, and first patent issuance Vancouver, British Columbia, August 16, 2021 – Filament Health Corp. (NEO:FH) (“Filament” or the “Company”), a leading exclusively-natural psychedelic drug development company, today released its second quarter unaudited financial results…
